Beta-blocker therapy and primary angioplasty What is the controversy?**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. by Faxon, David P.
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hDITORIAL COMMENT
eta-Blocker Therapy
nd Primary Angioplasty
hat Is the Controversy?*
avid P. Faxon, MD, FACC
hicago, Illinois
eta-blocker therapy has long been recommended for the
reatment of ST-elevation myocardial infarction (STEMI)
nd is listed as a class 1 indication in the American College
f Cardiology/American Heart Association (ACC/AHA)
uidelines for the treatment of acute myocardial infarction
MI) (1). Studies prior to the use of thrombolysis have
emonstrated both short- and long-term benefits, and a
eta-analysis of these trials showed a 25% reduction in
ortality at one year (2). Likewise, a similar analysis of the
tudies in patients treated with thrombolysis showed an
verall 23% reduction in mortality (3). Early intravenous
eta-blocker therapy also has been shown to improve both
hort-term and long-term outcome in the Thrombolysis in
See pages 1765, 1773, and 1780
yocardial Infarction II-B trial (4). In the Carvedilol Post
nfarction Survival Control in Left Ventricular Dysfunction
CAPRICORN) trial, high-risk STEMI patients with re-
uced left ventricular (LV) function who were treated with
he beta-blocker carvedilol realized a reduction in mortality
f 23% over a 2.5-year period (5). With a wealth of
nformation supporting the use of beta-blocker therapy, it is
urprising and somewhat disappointing that 30% to 50% of
atients with STEMI still failed to receive these agents (6).
f the data for their use are so strong, what is the contro-
ersy? Although there seems to be little question that
atients with STEMI, regardless of whether or not they
eceive thrombolysis, derive substantial benefits from both
ong- and short-term beta-blockade, there has been a
urprising paucity of studies that support the use of beta-
lockers after primary angioplasty in STEMI. Although it
ould seem logical to assume the same degree of benefit,
any physicians have not been convinced of either short- or
ong-term benefit of beta-blockade after primary angio-
lasty, given the lack of evidence of benefit after percuta-
eous coronary intervention (PCI). The rationale for beta
lockade in revascularized patients is unclear, particularly in
hose patients without any significant residual coronary
bstructions and an uncomplicated hospital course (7). In
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Section of Cardiology, Department of Medicine, University of Chicago,lhicago, Illinois.his issue of the Journal, three separate articles (8–10)
xplore the question of beta-blocker therapy in primary
ngioplasty.
Only a few studies have examined the benefit of beta-
locker therapy in patients receiving primary angioplasty. A
etrospective review of the Primary Angioplasty in Myocar-
ial Infarction (PAMI) studies demonstrated improved
utcome with beta-blocker use (11). In this study, 2,537
atients enrolled in four PAMI studies were pooled. Pa-
ients receiving pretreatment with beta-blockers before pri-
ary angioplasty were compared with those not receiving
retreatment. After adjustment for baseline differences be-
ween patient groups, a significantly lower incidence of
n-hospital death with use of beta-blocker therapy was
ound (1.3% vs. 3.7% p  0.0035). A strong trend toward a
ower mortality at one year was also reported (p  0.055).
owever, not all patients were receiving beta-blockers
uring the follow-up period (66% to 89%). When only
hose receiving beta-blockers during follow-up were in-
luded in the analysis, there was a significantly improved
ne-year mortality with its use (odds ratio [OR]  0.43; p
0.001). In this issue of the Journal, Kernis et al. (8)
xamined 2,442 patients with successful primary angioplasty
hat participated in four of the PAMI studies. This patient
roup was slightly different from the group in the previous
eport (two trials were the same, two were different from the
revious publication); however, the findings were remark-
bly similar. In this study the authors evaluated only
ost-procedural beta-blocker use after PCI on six-month
utcomes. Again, a significant reduction in mortality was
bserved (2.2 vs. 6.6; p  0.001), and the multivariate
nalysis demonstrated an OR remarkably similar to the first
tudy (OR  0.43; p  0.0016). Importantly, the authors
howed a survival benefit in high-risk sub-groups such as
hose with ejection fractions 50% (OR  0.34; p 
.0001) and those with multivessel disease (OR 0.26; p
.001).
Also, in this issue of the Journal, Halkin et al. (9)
valuated the effect of beta-blockers on 30-day mortality in
he 2,082 patients undergoing primary PCI for STEMI as
art of the Controlled Abciximab and Device Investigation
o Lower Late Angioplasty Complications trial, a random-
zed trial of balloon angioplasty versus stenting with or
ithout glycoprotein IIb/IIIa agent abciximab. The study
emonstrated a lower 30-day mortality in the beta-blocker
roup (1.5% vs. 2.8%; p 0.03). The improved survival was
ot realized at one year; although an absolute difference
etween groups (1.7%) was similar, suggesting the benefit
as largely an early benefit. The lack of long-term benefit,
owever, might not have been realized owing to the high
ercentage of patients in both groups receiving beta-
lockers during follow-up (86% for initial beta-blocker use
s. 70% for initial non-beta-blocker users). The benefit,
owever, was confined to those who were not receivingong-term beta-blocker therapy before hospital admission.
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May 19, 2004:1788–90 Editorial Commenthis finding is surprising because a benefit has been
bserved previously in such patients (12). Together, these
tudies provide powerful support for the use of beta-blocker
herapy in patients with STEMI undergoing primary an-
ioplasty, and they support the ACC/AHA guideline rec-
mmendations (1). Pre-procedural administration resulted
n a 50% to 65% reduction in hospital mortality. Likewise,
ong-term beta-blocker therapy had a favorable impact on
ong-term outcome by an equal degree.
The mechanism of benefit from beta-blocker therapy in
TEMI is still unclear. It has been suggested that early
eta-blocker treatment decreases myocardial oxygen con-
umption, favorably influences coronary blood flow, and
educes infarct size. The improvements in ejection fraction
n a study by Halkin et al. (9) support a reduction in the
nfarct size as contributing. Another mechanism of benefit
ight be a reduction in procedural MI. In a recent retro-
pective study by Sharma et al. (13), 1,676 patients under-
oing non-STEMI coronary interventions were reviewed.
revious beta-blocker therapy reduced the incidence of
ost-procedural creatine kinase-MB release and improved
hort-term mortality over a 15-month period (13). It
emains controversial whether intravenous or intracoronary
eta-blockers immediately before PCI reduce peri-
rocedural risk of MI after angioplasty (14,15). However,
ong-term therapy, particularly in high-risk patients under-
oing PCI, has shown benefit (16). Another potential
echanism for benefit is a reduction in fatal ventricular
rrhythmias. In a study from the PAMI group, Mehta et al.
10), in this issue of the Journal, demonstrated a reduced
ncidence of procedural ventricular tachycardia/ventricular
brillation (VT/VF) in patients receiving beta-blocker ther-
py and undergoing primary angioplasty. Although VT/VF
as rare (4.3%), it was a marker of poor outcome. Interest-
ngly, this study failed to demonstrate a benefit with
eta-blockers on post-procedural or late VT/VF. It has been
ostulated that the anti-ischemic effects of beta-blockers
ay contribute to the improved long-term outcome. How-
ver, in both the PAMI and Controlled Abciximab and
evice Investigation to Lower Late Angioplasty Compli-
ations trials reported in this issue of the Journal, beta-
lockade was not associated with the reduction in ischemic-
riven target vessel revascularization or re-infarction.
Is the case closed on beta-blockers and STEMI under-
oing primary angioplasty? Not quite yet. Although these
tudies are persuasive, we still have not had a single
andomized trial of beta-blocker therapy in primary angio-
lasty. The potential selection bias that naturally occurs in
on-randomized studies diminishes the powers of the ob-
ervations reported in this issue of the Journal. It is also not
lear whether all patients receiving primary angioplasty
enefit from pre-procedural or long-term oral beta-blocker
herapy. Kernis et al. (8) showed that in patients with either
normal ejection fraction or single-vessel disease and no
n-hospital major adverse coronary events, long-term ben-
fits of beta-blocker therapy could not be demonstrated.hat should we do today based on the available data? It is
lear that all patients without contraindication should re-
eive beta-blockers before primary angioplasty and that
hose receiving long-term oral beta-blockers before admis-
ion should continue to receive beta-blockers. Patients who
evelop an in-hospital complication, have reduced LV
unction, or have multi-vessel disease derive the greatest
enefit from long-term oral therapy. The question remains,
owever, whether a patient with normal ejection fraction
nd single-vessel disease who undergoes a successful angio-
lasty receives any benefit from either short- or long-term
eta-blocker therapy. This question remains an unanswered
ne and will need to await further data from clinical trials to
e resolved. In the absence of additional studies, the data
ould strongly support the current guidelines for the use of
eta-blockers in all eligible patients, regardless of the
evascularization strategy. In primary PCI, it is clear that
re-procedural beta-blocker therapy also is of significant
enefit. Our major challenge in the future to ensure that all
ligible patients with STEMI are treated with beta-blockers
oth before angioplasty and during long-term follow-up.
he health implications of widespread use of beta-blockers
fter MI are enormous, given the magnitude of benefit
eported in clinical trials. National efforts to improve com-
liance with guidelines, such as the AHA’s “Get with the
uidelines” program, have already shown improvements in
he use of beta-blockers and other secondary prevention
reatments. Let’s hope that the benefit now observed in
atients with primary angioplasty will help further increase
heir use.
eprint requests and correspondence: Dr. David P. Faxon,
hief, Section of Cardiology, The University of Chicago, 5841
outh Maryland Avenue, MC 6080, Chicago, Illinois 60637.
-mail: dfaxon@medicine.bsd.uchicago.edu.
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